21 results on '"Karolina Pytka"'
Search Results
2. The selective 5-HT1A receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress
- Author
-
Marek Jamrozik, Joanna Sniecikowska, Alicja Gawalska, Monika Głuch-Lutwin, Kinga Sałaciak, Karolina Pytka, Marcin Kołaczkowski, and Adrian Newman-Tancredi
- Subjects
Male ,medicine.medical_specialty ,Population ,Aminopyridines ,Biased agonism ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Piperidines ,Postsynaptic potential ,Internal medicine ,medicine ,Animals ,5-HT1A receptor ,Single-Blind Method ,education ,Receptor ,5-HT receptor ,030304 developmental biology ,Original Investigation ,Pharmacology ,0303 health sciences ,education.field_of_study ,F15599 ,Dose-Response Relationship, Drug ,Chemistry ,Depression ,Serotonin 5-HT1 Receptor Agonists ,F13714 ,Antidepressive Agents ,Disease Models, Animal ,Endocrinology ,Pyrimidines ,Chronic Disease ,Receptor, Serotonin, 5-HT1A ,Autoreceptor ,Memory consolidation ,030217 neurology & neurosurgery ,Locomotion ,Stress, Psychological ,Behavioural despair test - Abstract
Rationale The prevalence of depression is ever-increasing throughout the population. However, available treatments are ineffective in around one-third of patients and there is a need for more effective and safer drugs. Objectives The antidepressant-like and procognitive effects of the “biased agonists” F15599 (also known as NLX-101) which preferentially targets postsynaptic 5-HT1A receptors and F13714, which targets 5-HT1A autoreceptors, were investigated in mice. Methods Antidepressant-like properties of the compounds and their effect on cognitive functions were assessed using the forced swim test (FST) and the novel object recognition (NOR), respectively. Next, we induced a depressive-like state by an unpredictable chronic mild stress (UCMS) procedure to test the compounds’ activity in the depression model, followed by measures of sucrose preference, FST, and locomotor activity. Levels of phosphorylated cyclic AMP response element-binding protein (p-CREB) and phosphorylated extracellular signal-regulated kinase (p-ERK1/2) were also determined. Results F15599 reduced immobility time in the FST over a wider dose-range (2 to 16 mg/kg po) than F13714 (2 and 4 mg/kg po), suggesting accentuated antidepressant-like properties in mice. F15599 did not disrupt long-term memory consolidation in the NOR at any dose tested, while F13714 impaired memory formation, notably at higher doses (4–16 mg/kg). In UCMS mice, a single administration of F15599 and F13714 was sufficient to robustly normalize depressive-like behavior in the FST but did not rescue disrupted sucrose preference. Both F15599 and F13714 rescued cortical and hippocampal deficits in p-ERK1/2 levels of UCMS mice but did not influence the p-CREB levels. Conclusions Our studies showed that 5-HT1A receptor biased agonists such as F13714 and especially F15599, due to its less pronounced side effects, might have potential as fast-acting antidepressants.
- Published
- 2021
3. The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and β-arrestin signalling
- Author
-
Karolina Pytka, Leszek Nowiński, Marek Bednarski, Małgorzata Szafarz, Emma J. Mitchell, Henryk Marona, Kinga Sałaciak, Monika Głuch-Lutwin, Agata Siwek, Magdalena Jastrzębska-Więsek, Anna Partyka, Marcin Kołaczkowski, Natalia Szkaradek, Anna Wesołowska, Jacek Sapa, and Grzegorz Kazek
- Subjects
Male ,Stereochemistry ,Xanthones ,Xanthone Derivatives ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Arrestin ,Animals ,Pharmacology (medical) ,Receptor ,beta-Arrestins ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Behavior, Animal ,Chemistry ,Antidepressive Agents ,Tail suspension test ,Psychiatry and Mental health ,Piperazine ,Signalling ,Receptor, Serotonin, 5-HT1A ,5-HT1A receptor ,030217 neurology & neurosurgery ,Signal Transduction ,Behavioural despair test - Abstract
Background: Our previous studies showed that xanthone derivatives with N-(2-methoxyphenyl)piperazine fragment have an affinity to the 5-HT1A receptor and show antidepressant-like properties in rodents. In this study, we tested three xanthone derivatives, HBK-1 (R, S) and its enantiomers, in which we increased the distance between the piperazine and xanthone fragments by using a hydroxypropoxy linker. We hypothesized that this would increase the binding to the 5-HT1A receptor and consequently, pharmacological activity. Aims: We aimed to assess the in vitro and in vivo pharmacological activity of the xanthone derivatives. Methods: We evaluated the in vitro affinity for serotonin 5-HT1A and 5-HT2A receptors and serotonin transporter. We also determined the intrinsic activity at the 5-HT1A receptor. We investigated the antidepressant-like properties and safety after acute administration (dose range: 1.25–20 mg/kg) using the forced swim, tail suspension, locomotor activity, rotarod and chimney tests in mice. We also evaluated the basic pharmacokinetic parameters. Results: Our results indicated that the compounds showed a high affinity for the 5-HT1A receptor but very weak antagonistic properties in the Ca2+ mobilization assay; however, they showed significant agonistic properties in the β-arrestin recruitment assay. In both behavioural tests the studied xanthone derivatives showed antidepressant-like activity. Pre-treatment with p-chlorophenylalanine or WAY-100635 abolished their antidepressant-like activity. None of the compounds caused motor impairments at antidepressant-like doses. The racemate penetrated the blood–brain barrier and had a relatively high bioavailability after intraperitoneal administration. Conclusions: Xanthone derivatives with N-(2-methoxyphenyl)piperazine fragment and hydroxypropoxy linker show increased binding to the 5-HT1A receptor and may represent an attractive putative treatment candidate for depression.
- Published
- 2020
4. Protease-activated receptor 2 activation induces behavioural changes associated with depression-like behaviour through microglial-independent modulation of inflammatory cytokines
- Author
-
Serge Moudio, Ashleigh Willis, Karolina Pytka, Roua Abulkassim, Ros R. Brett, Jack F. Webster, Christian Wozny, Mark Barbour, Hui-Rong Jiang, David G. Watson, Josie C. van Kralingen, Scott M. MacKenzie, Michael Daniels, Barry W. McColl, Sandra Sossick, Hugh N. Nuthall, and Trevor J. Bushell
- Subjects
Pharmacology ,Open-field test ,Inflammation ,Protease-activated receptor-2 ,Depressive Disorder, Major ,Sucrose preference ,Depression ,RS ,Mice ,RC0321 ,Cytokines ,Animals ,Humans ,Receptor, PAR-2 ,Microglia ,Original Investigation - Abstract
Rationale Major depressive disorder (MDD) is a leading cause of disability worldwide but currently prescribed treatments do not adequately ameliorate the disorder in a significant portion of patients. Hence, a better appreciation of its aetiology may lead to the development of novel therapies. Objectives In the present study, we have built on our previous findings indicating a role for protease-activated receptor-2 (PAR2) in sickness behaviour to determine whether the PAR2 activator, AC264613, induces behavioural changes similar to those observed in depression-like behaviour. Methods AC264613-induced behavioural changes were examined using the open field test (OFT), sucrose preference test (SPT), elevated plus maze (EPM), and novel object recognition test (NOR). Whole-cell patch clamping was used to investigate the effects of PAR2 activation in the lateral habenula with peripheral and central cytokine levels determined using ELISA and quantitative PCR. Results Using a blood–brain barrier (BBB) permeable PAR2 activator, we reveal that AC-264613 (AC) injection leads to reduced locomotor activity and sucrose preference in mice but is without effect in anxiety and memory-related tasks. In addition, we show that AC injection leads to elevated blood sera IL-6 levels and altered cytokine mRNA expression within the brain. However, neither microglia nor peripheral lymphocytes are the source of these altered cytokine profiles. Conclusions These data reveal that PAR2 activation results in behavioural changes often associated with depression-like behaviour and an inflammatory profile that resembles that seen in patients with MDD and therefore PAR2 may be a target for novel antidepressant therapies.
- Published
- 2022
5. Mitogen-activated protein kinase phosphatase-2 deletion modifies ventral tegmental area function and connectivity and alters reward processing
- Author
-
Mark A. Ungless, Ros R. Brett, Trevor J. Bushell, Kyoko Tossell, Neil Dawson, Karolina Pytka, and Robin Plevin
- Subjects
Hippocampus ,Biology ,Nucleus accumbens ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Reward ,Dopamine ,Protein Phosphatase 1 ,medicine ,Animals ,Protein kinase A ,030304 developmental biology ,Mice, Knockout ,0303 health sciences ,General Neuroscience ,Ventral Tegmental Area ,Ventral tegmental area ,Amphetamine ,medicine.anatomical_structure ,Mitogen-activated protein kinase ,Synaptic plasticity ,RC0321 ,biology.protein ,Excitatory postsynaptic potential ,Mitogen-Activated Protein Kinase Phosphatases ,Mitogen-Activated Protein Kinases ,Protein Tyrosine Phosphatases ,Neuroscience ,Gene Deletion ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Mitogen-activated protein kinases (MAPKs) regulate normal brain functioning, and their dysfunction is implicated in a number of brain disorders. Thus, there is great interest in understanding the signalling systems that control MAPK functioning. One family of proteins that contribute to this process, the mitogen-activated protein kinase phosphatases (MKPs), directly inactivate MAPKs through dephosphorylation. Recent studies have identified novel functions of MKPs in foetal development, the immune system, cancer and synaptic plasticity and memory. In the present study, we performed an unbiased investigation using MKP-2-/- mice to assess whether MKP-2 plays a global role in modulating brain function. Local cerebral glucose utilization is significantly increased in the ventral tegmental area (VTA) of MKP-2-/- mice, with connectivity analysis revealing alterations in VTA functional connectivity, including a significant reduction in connectivity to the nucleus accumbens and hippocampus. In addition, spontaneous excitatory postsynaptic current frequency, but not amplitude, onto putative dopamine neurons in the VTA is increased in MKP-2-/- mice, which indicates that increased excitatory drive may account for the increased VTA glucose utilization. Consistent with modified VTA function and connectivity, in behavioural tests MKP-2-/- mice exhibited increased sucrose preference and impaired amphetamine-induced hyperlocomotion. Overall, these data reveal that MKP-2 plays a role in modulating VTA function and that its dysfunction may contribute to brain disorders in which altered reward processing is present.
- Published
- 2020
6. Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model
- Author
-
Lee Wheeler, Jacek Sapa, Katarzyna Kieć-Kononowicz, Magdalena Kotańska, Kamil Mika, Kinga Sałaciak, and Karolina Pytka
- Subjects
Male ,Agonist ,medicine.medical_specialty ,Elevated plus maze ,Pitolisant ,medicine.drug_class ,Clinical Biochemistry ,Sigma-1 receptor ,Toxicology ,Biochemistry ,Anxiolytic ,RS ,Mice ,03 medical and health sciences ,Behavioral Neuroscience ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Corticosterone ,Internal medicine ,medicine ,Animals ,Inverse agonist ,pitolisant ,Biological Psychiatry ,metabolic disturbance ,Pharmacology ,Behavior, Animal ,Depression ,business.industry ,corticosterone ,depressive-like behavior ,030227 psychiatry ,Disease Models, Animal ,Endocrinology ,chemistry ,$H_{3}$ histamine receptor ,Histamine H3 receptor ,business ,030217 neurology & neurosurgery ,Histamine ,Histamine H3 Antagonists - Abstract
Purpose Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also compensate for metabolic disorders, which affect glucose or triglyceride levels. In previous studies, we have shown that pitolisant, a histamine H3 receptor antagonist/inverse agonist and σ1 receptor agonist, prevented the development of certain metabolic and depressive-like disorders in mice that have been treated chronically with olanzapine. Methods As a continuation of our previous experiments, this study aimed to investigate the antidepressant- and anxiolytic-like activity of pitolisant in mice using the corticosterone-induced depression model. The forced swim and the elevated plus maze tests were used as behavioral endpoints. We also studied the effect pitolisant had on the level of acetoacetic acid in the urine as well as the glucose tolerance and body weight of the mice that had been administered corticosterone. Results Pitolisant (10 mg/kg b.w.) did not prevent depressive-like behavior in mice during the chronic corticosterone administration but did counteract anxiety-like behavior, whilst fluoxetine (10 mg/kg) was shown to protect the mice from both of these behaviors. None of the treatments that were used in the study showed an effect on the locomotor activity of the mice. Pitolisant did not prevent an increase in acetoacetic acid levels in the urine, nor did it improve glucose tolerance in the tested mice. Conclusion Although literature data indicates that there is significant potential for finding an antidepressant and anti-diabetic drug among the histamine H3 and σ1 receptor ligands, in our study, pitolisant was shown to only slightly compensate for corticosterone-induced abnormalities. However, further research will be required to study pitolisant's anxiolytic-like activity.
- Published
- 2020
7. Synthesis and activity of di- or trisubstituted N-(phenoxyalkyl)- or N-2-[2-(phenoxy)ethoxy]ethyl piperazine derivatives on the central nervous system
- Author
-
Dorota Żelaszczyk, Karolina Słoczyńska, Anna Gryboś, Monika Głuch-Lutwin, Karolina Pytka, Anna Furgała, Anna M. Waszkielewicz, Kinga Sałat, Magdalena Jakubczyk, Katarzyna Pańczyk, Paweł Żmudzki, Agata Siwek, Elżbieta Pękala, Adam Bucki, Anna Rapacz, Marcin Kołaczkowski, and Henryk Marona
- Subjects
Central Nervous System ,Models, Molecular ,0301 basic medicine ,medicine.drug_class ,medicine.medical_treatment ,Clinical Biochemistry ,Analgesic ,Pharmaceutical Science ,Motor Activity ,Pharmacology ,01 natural sciences ,Biochemistry ,Anxiolytic ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Discovery ,medicine ,Animals ,Piperazine ,Molecular Biology ,5-HT receptor ,Dose-Response Relationship, Drug ,Molecular Structure ,Organic Chemistry ,Antagonist ,Serotonin Receptor Agonists ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,030104 developmental biology ,Anticonvulsant ,Mechanism of action ,chemistry ,Receptors, Serotonin ,Molecular Medicine ,Anticonvulsants ,medicine.symptom ,Injections, Intraperitoneal ,Behavioural despair test - Abstract
Aim of the study was evaluation of anxiolytic, antidepressant, anticonvulsant and analgesic activity in a series of a consistent group of compounds. A series of eleven new N-(phenoxyalkyl)- or N-{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives has been obtained. Their affinity towards 5-HT1A, 5-HT2A, 5-HT6, 5-HT7, D2 and α1 receptors has been assessed, and then functional assays were performed. The compounds were evaluated in mice, i.p. for their antidepressant-like (forced swim test), locomotor, anxiolytic-like (four-plate test) activities as well as – at higher doses – for anticonvulsant potential (MES) and neurotoxicity (rotarod). Two compounds (3, 6) were also evaluated for their analgesic activity in neuropathic pain models (streptozocin test, oxaliplatin test) and they were found active against allodynia in diabetic neuropathic pain at 30 mg/kg. Among the compounds, anxiolytic-like, anticonvulsant or analgesic activity was observed but antidepressant-like activity was not. One of the two most interesting compounds is 1-{2-[2-(2,4,6-trimethylphenoxy)ethoxy]ethyl}-4-(2-methoxyphenyl)piperazine dihydrochloride (9), exhibiting anxiolytic and anticonvulsant activity in mice, i.p. 30 min after administration (at 2.5 mg/kg and ED50 = 26.33 mg/kg, respectively), which can be justified by the receptor profile: 5-HT1A Ki = 5 nM (antagonist), 5-HT7 Ki = 70 nM, α1 Ki = 15 nM, D2 Ki = 189 nM (antagonist). Another interesting compound is 1-[3-(2,4,6-trimethylphenoxy)propyl]-4-(4-methoxyphenyl)piperazine dihydrochloride (3), exhibiting anxiolytic, anticonvulsant and antiallodynic activity in mice, i.p., 30 min after administration (at 10 mg/kg, ED50 = 23.50 mg/kg, at 30 mg/kg, respectively), which can be related with 5-HT1A weak antagonism (Ki = 146 nM), or other possible mechanism of action, not evaluated within presented study. Additionally, for the most active compound in the four-plate test (7), molecular modeling was performed (docking to receptors 5-HT1A, 5-HT2A, 5-HT7, D2 and α1A).
- Published
- 2018
8. HBK-14 and HBK-15, triple 5-HT
- Author
-
Karolina, Pytka, Katarzyna, Socała, Anna, Rapacz, Dorota, Nieoczym, Mateusz, Pieróg, Anna, Gryboś, Agata, Siwek, Anna, Waszkielewicz, and Piotr, Wlaź
- Subjects
Male ,Electroshock ,Phenyl Ethers ,Voltage-Gated Sodium Channels ,Motor Activity ,Antidepressive Agents ,Piperazines ,Disease Models, Animal ,Mice ,Random Allocation ,Anti-Anxiety Agents ,Seizures ,Receptors, Serotonin ,Receptor, Serotonin, 5-HT1A ,Animals ,Pentylenetetrazole ,Anticonvulsants ,Muscle Strength ,Serotonin Antagonists ,Receptors, Serotonin, 5-HT3 ,Photic Stimulation - Abstract
Most antidepressants lower seizure threshold, which might be due to the modulation of serotonergic neurotransmission. Here, we investigated the effects of two 5-HT
- Published
- 2017
9. Single Administration of HBK-15-a Triple 5-HT
- Author
-
Karolina, Pytka, Monika, Głuch-Lutwin, Magdalena, Kotańska, Anna, Waszkielewicz, Agnieszka, Kij, and Maria, Walczak
- Subjects
Male ,Serotonin ,5-HT1A receptor antagonist ,Behavior, Animal ,Depression ,Phenyl Ethers ,Guinea Pigs ,5-HT3 receptor antagonist ,CD-1 mice ,Piperazines ,Article ,Blood–brain barrier ,Disease Models, Animal ,Mice ,nervous system ,Corticosterone-induced model of depression ,Ileum ,Receptors, Serotonin ,Animals ,Pharmacokinetics ,Serotonin Antagonists ,Corticosterone ,5-HT7 receptor antagonist ,Muscle Contraction - Abstract
Studies suggest that the blockade of 5-HT1A, 5-HT7, and 5-HT3 receptor may increase the speed of antidepressant response. 1-[(2,6-Dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-15), dual 5-HT1A and 5-HT7 antagonists, showed significant antidepressant- and anxiolytic-like properties in our previous tests in rodents. In this study, we aimed to investigate their antidepressant potential using mouse model of corticosterone-induced depression. We chose sucrose preference test, forced swim test, and elevated plus maze to determine anhedonic-, antidepressant-, and anxiolytic-like activities. We also evaluated the influence of the active compound on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus. Moreover, for both compounds, we performed biofunctional (5-HT3 receptor) and pharmacokinetic studies. We found that HBK-14 and HBK-15 were potent 5-HT3 receptor antagonists. HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration permeated the blood–brain barrier with brain/plasma ratio lower than 1. The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15. Chronic administration of HBK-15 (1.25 mg/kg) and fluoxetine (10 mg/kg) protected corticosterone-treated mice from anhedonic-, depressive-, and anxiety-like behaviors, as well as decreases in BDNF and NGF levels in the hippocampus. HBK-14 (2.5 mg/kg) counteracted anxiety-like behaviors in corticosterone-treated mice. Single administration of HBK-15 (1.25 mg/kg) and ketamine (1 mg/kg) reversed depression-like behavior and regulated decreased BDNF level in the hippocampus in corticosterone-treated mice. Our results suggest that simultaneous blockade of serotonergic 5-HT1A, 5-HT7, and 5-HT3 receptors might accelerate antidepressant response.
- Published
- 2017
10. HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels
- Author
-
Anna M. Waszkielewicz, Paulina Janiszewska, Monika Głuch-Lutwin, Magdalena Jakubczyk, Magdalena Kotańska, Maria Walczak, Elżbieta Żmudzka, and Karolina Pytka
- Subjects
0301 basic medicine ,Male ,Elevated plus maze ,medicine.medical_specialty ,Sucrose ,Hippocampus ,Serotonergic ,Piperazines ,03 medical and health sciences ,Behavioral Neuroscience ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Corticosterone ,Internal medicine ,Adrenal Glands ,Nerve Growth Factor ,medicine ,Animals ,Prefrontal cortex ,Maze Learning ,Swimming ,Volume of distribution ,Dose-Response Relationship, Drug ,business.industry ,Brain-Derived Neurotrophic Factor ,Mental Disorders ,Phenyl Ethers ,Brain ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,Nerve growth factor ,chemistry ,Cytokines ,Serotonin Antagonists ,business ,030217 neurology & neurosurgery ,Locomotion ,Stress, Psychological ,Behavioural despair test - Abstract
Unlike majority of current antidepressants, HBK-15-a 5-HT1A and 5-HT7 receptor antagonist - showed memory-enhancing properties. In this study, we aimed to further characterize pharmacological profile of HBK-15 and investigate its antidepressant- and anxiolytic-like activity in the mouse model of unpredictable chronic mild stress. We used sucrose consumption test, forced swim test and elevated plus maze test as behavioral endpoints. We also evaluated the influence of HBK-15 on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus and prefrontal cortex, as well as body weight, relative adrenal glands weight and plasma corticosterone level in the stressed mice. We utilized LC/MS/MS method to determine HBK-15 concentration in plasma and brain. We evaluated pharmacokinetic profile and distribution to brain of HBK-15 (2.5mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration in CD-1 mice. HBK-15 (2.5mg/kg but not 1.25mg/kg) and fluoxetine (10mg/kg) protected stressed mice from anhedonic-, depressive- and anxiety-like behaviors, decreases in the BDNF and NGF levels in the hippocampus and prefrontal cortex, increases in plasma corticosterone levels and relative adrenal glands weight. The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%. HBK-15 administered i.v. and i.p. significantly penetrated brain. Our results suggest that the blockade of serotonergic 5-HT1A and 5-HT7 receptors might be beneficial in the treatment of depressive disorders with cognitive dysfunction.
- Published
- 2017
11. PRELIMINARY EVALUATION OF CENTRAL NERVOUS SYSTEM ACTIVITY OF (E)-N-2-METHYL-3-PHENYLPROP-2-ENYL ((E)-N- α-METHYLCINNAMYL) DERIVATIVES OF SELECTED AMINOALKANOLS
- Author
-
Agnieszka, Gunia-Krzyzak, Karolina, Pytka, Karolina, Słoczyńska, Anna M, Waszkielewicz, Grzegorz, Satała, Andrzej J, Bojarski, Jacek, Sapa, Barbara, Filipek, Marek, Cegła, Elzbieta, Pekala, and Henryk, Marona
- Subjects
Electroshock ,Behavior, Animal ,Molecular Structure ,Hydrogen Bonding ,Motor Activity ,Antidepressive Agents ,Rats, Sprague-Dawley ,Disease Models, Animal ,Methylamines ,Mice ,Structure-Activity Relationship ,Anti-Anxiety Agents ,Cinnamates ,Seizures ,Microsomes, Liver ,Animals ,Pentylenetetrazole ,Anticonvulsants ,Neurotoxicity Syndromes ,Hydrophobic and Hydrophilic Interactions ,Biotransformation - Abstract
A series of (E)-α-methylcinnamyl derivatives of selected aminoalkanols was synthetized and evaluated for activity in central nervous system. All compounds were tested as anticonvulsants and one additionally in antidepressant- and anxiolytic-like assays. The compounds possessed pharmacophoric elements regarded as beneficial for anticonvulsant activity: hydrophobic unit and two hydrogen bonds donor/acceptor features. The compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and subcutaneous pentetrazole (scPTZ) induced seizures as well as neurotoxicity assessments. Eight of the tested substances showed protection in MES test at the dose of 100 mg/kg. The derivative of 2-aminopropan-1-ol was also tested in 6-Hz test in mice i.p. and showed anticonvulsant activity but at the same time the neurotoxicity was noted. The derivative of 2-amino-1-phenylethanol which possessed additional hydrophobic unit in aminoalkanol moiety was tested in other in vivo assays to evaluate antidepressant- and anxiolytic-like activity. The compound proved beneficial properties especially as anxiolytic agent remaining active in four-plate test in mice at the dose of 2.5 mg/kg (i.p.). In vitro biotransformation studies of 2-amino-1-phenylethanol derivative carried out in mouse liver microsomal assay indicated two main metabolites as a result of aliphatic and aromatic hydroxylation or aliphatic carbonylation. To identify possible mechanism of action, we evaluated serotonin receptors (5-HT1A, 5-HT6 and 5-HT7) binding affinities of the compounds but none of them proved to bind to any of tested receptors.
- Published
- 2016
12. Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A
- Author
-
Anna, Dziubina, Karina, Szmyd, Małgorzata, Zygmunt, Jacek, Sapa, Magdalena, Dudek, Barbara, Filipek, Anna, Drabczyńska, Michał, Załuski, Karolina, Pytka, and Katarzyna, Kieć-Kononowicz
- Subjects
Male ,Immobilization ,Mice ,Anti-Anxiety Agents ,Dose-Response Relationship, Drug ,Depression ,Purinergic Agents ,Drug Evaluation, Preclinical ,Animals ,Anxiety ,Antidepressive Agents - Abstract
It has recently been suggested that the adenosine AIn the present study, imidazo- and pyrimido[2,1-f]purinedione derivatives (KD 66, KD 167, KD 206) with affinity to AThe results showed the antidepressant-like activity of pyrimido- and imidazopurinedione derivatives (i.e. KD 66, KD 167 and KD 206) in acute and chronic behavioral tests in mice. KD 66 revealed an anxiolytic-like effect, while KD 167 increased anxiety behaviors. KD 206 had no effect on anxiety. Furthermore, none of the tested compounds increased locomotor activity.Available data support the proposition that the examined compounds with adenosine A
- Published
- 2016
13. H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
- Author
-
Katarzyna Kieć-Kononowicz, Adrian Olczyk, Karolina Pytka, Magdalena Dudek, Aleksandra Rak, Marek Bednarski, Marcin Kołaczkowski, Elżbieta Żmudzka, Kamil Kuder, and Jacek Sapa
- Subjects
Depression-like symptoms ,Locomotor activity ,0301 basic medicine ,Olanzapine ,Pitolisant ,medicine.drug_class ,medicine.medical_treatment ,Sedation ,Clinical Neurology ,Atypical antipsychotic ,Pharmacology ,Biochemistry ,Article ,Benzodiazepines ,Mice ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Histamine receptor ,0302 clinical medicine ,Piperidines ,medicine ,Animals ,Receptors, Histamine H3 ,Antipsychotic ,Triglycerides ,Dose-Response Relationship, Drug ,Depression ,business.industry ,Antagonist ,030104 developmental biology ,chemistry ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Locomotion ,030217 neurology & neurosurgery ,Histamine ,Antipsychotic Agents ,Histamine H3 Antagonists ,medicine.drug - Abstract
The use of atypical antipsychotic drugs like olanzapine is associated with side effects such as sedation and depression-like symptoms, especially during the initial period of the use. It is believed that the occurrence of these undesirable effectsis mainly the result of the histamine H1receptors blockade by olanzapine. In addition, use of olanzapine increases the level of triglycerides in the blood, which correlates with growing obesity. The aim of this study was to investigate the influence of pitolisant – H3 histamine antagonist - on subchronic olanzapine-induced depresion-like symptoms, sedation and hypertriglicerydemia. Forced swim test was conducted to determinate depressive-like effect of olanzapine and antidepressive-like activity during the co-administered pitolisant. The test was performed after the first and fifteenth day of the treatment of the mice. The spontaneous activity of the mice was measured on the fourteenth day of the treatment with a special, innovative RFID-system (Radio-frequency identification system) – TraffiCage (TSE-Systems, Germany). Triglyceride levels were determined on the sixteenth day of the experiment after 15 cycles of drug administration. Daily olanzapine treatment (4 mg/kg b.w., i.p., d.p.d) for 15 days significantly induces sedation (p
- Published
- 2016
14. Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action
- Author
-
Magdalena Dudek, Barbara Filipek, Elżbieta Żmudzka, Marek Bednarski, Grzegorz Satała, Karolina Pytka, Anna M. Waszkielewicz, Leszek Nowiński, Henryk Marona, Andrzej J. Bojarski, Monika Kubacka, Agata Siwek, and Szczepan Mogilski
- Subjects
0301 basic medicine ,Agonist ,Male ,medicine.medical_specialty ,medicine.drug_class ,Clinical Biochemistry ,Guinea Pigs ,Pharmacology ,Toxicology ,Serotonergic ,Biochemistry ,Piperazines ,Body Temperature ,03 medical and health sciences ,Behavioral Neuroscience ,Mice ,Radioligand Assay ,0302 clinical medicine ,Internal medicine ,medicine ,Animals ,Humans ,Rats, Wistar ,Receptor ,Biological Psychiatry ,5-HT receptor ,Behavior, Animal ,Chemistry ,Receptor antagonist ,Antidepressive Agents ,Rats ,030104 developmental biology ,Endocrinology ,Mechanism of action ,Receptors, Serotonin ,Serotonin ,medicine.symptom ,030217 neurology & neurosurgery ,Endogenous agonist - Abstract
Since serotonin (5-HT) is strongly involved in the etiology and pathophysiology of depression, the development of new antidepressants is still based on the serotonergic system. The complexity of serotonergic system provides an opportunity for the development of compounds with multiple and complementary mechanism of action. This study describes serotonin receptor profile, functional characterization, and pharmacological in vivo evaluation of new aroxyalkyl derivatives of 2-methoxyphenylpiperazine. The obtained results allowed for the identification of compound 3, (1-[3-(2,6-dimethylphenoxy)propyl]-4-(2-methoxyphenyl)piperazine hydrochloride), a partial 5-HT1A receptor agonist, and 5-HT2A receptor antagonist, with high affinity toward 5-HT7 receptors, showing antidepressant- and anxiolytic-like properties. Moreover, 5-HT1A receptor activation is crucial for the antidepressant-like activity of compound 3. The rest of the compounds (except compounds 1 and 9) showed antidepressant but not anxiolytic-like properties, which did not result from 5-HT1A receptors activation. Furthermore, the compounds are 5-HT1A and weak 5-HT3 receptors antagonists, and some of them 5-HT2A antagonists. Moreover, none of the studied compounds impaired motor coordination at antidepressant-like doses. Since the studied compounds exhibited activity in behavioral assays and interacted with various receptors, the results of our experiments are very promising and require further studies.
- Published
- 2016
15. HBK-7 - A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties
- Author
-
Adrian Olczyk, Adam Galuszka, Karolina Pytka, Jacek Sapa, Monika Głuch-Lutwin, Agata Siwek, Henryk Marona, Barbara Filipek, Małgorzata Zygmunt, Waszkielewicz Anna Maria, Barbara Mordyl, Grzegorz Kazek, and Anna Rapacz
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Intrinsic activity ,medicine.drug_class ,Xanthones ,Clinical Biochemistry ,Motor Activity ,Serotonin 5-HT1 Receptor Antagonists ,Pharmacology ,Toxicology ,Serotonergic ,Biochemistry ,Piperazines ,Rotarod performance test ,Mice ,Radioligand Assay ,03 medical and health sciences ,Behavioral Neuroscience ,0302 clinical medicine ,Receptors, Adrenergic, alpha-2 ,Internal medicine ,Dopamine receptor D2 ,Avoidance Learning ,medicine ,Animals ,Biological Psychiatry ,5-HT receptor ,Serotonin Plasma Membrane Transport Proteins ,Receptors, Dopamine D2 ,Chemistry ,Immobility Response, Tonic ,Receptor antagonist ,Mianserin ,Antidepressive Agents ,030104 developmental biology ,Endocrinology ,Rotarod Performance Test ,Receptor, Serotonin, 5-HT1A ,5-HT1A receptor ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Xanthone derivatives possess many biological properties, including neuroprotective, antioxidant or antidepressant-like. In this study we aimed to investigate antidepressant- and anxiolytic-like properties of a new xanthone derivative - 6-methoxy-4-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one (HBK-7), as well as its possible mechanism of action, and the influence on cognitive and motor function. HBK-7 in our earlier studies showed high affinity for serotonergic 5-HT1A receptor. We determined the affinity of HBK-7 for CNS receptors and transporters using radioligand assays and examined its intrinsic activity towards 5-HT1A receptor. We evaluated antidepressant- and anxiolytic-like activity of HBK-7 in the mouse forced swim test, and four-plate test, respectively. We examined the influence on locomotor activity in mice to determine if the effect observed in the forced swim test was specific. We used step-through passive avoidance and rotarod tests to evaluate the influence of HBK-7 on cognitive and motor function, respectively. HBK-7 showed moderate affinity for dopaminergic D2 receptor and very low for serotonergic 5-HT2A, adrenergic α2 receptors, as well as serotonin transporter. Functional studies revealed that HBK-7 was a 5-HT1A receptor antagonist. HBK-7 (10mg/kg) decreased immobility time in the forced swim test. Combined treatment with sub-effective doses of HBK-7 and fluoxetine reduced immobility of mice in the forced swim test. Pretreatment with p-chlorophenylalanine and WAY-100,635 antagonized the antidepressant-like effect of HBK-7. Neither of the treatments influenced locomotor activity of mice. HBK-7 at antidepressant-like dose did not impair memory or motor coordination in mice. We demonstrated that HBK-7 was a 5-HT1A receptor antagonist with potent, comparable to mianserin, antidepressant-like activity. HBK-7 mediated its effect through serotonergic system and its antidepressant-like action required the activation of 5-HT1A receptors. At active dose it did not influence cognitive and motor function. Since 5-HT1A receptor antagonists may accelerate the occurrence of antidepressant effect, our findings highlight their potential as future antidepressants.
- Published
- 2016
16. The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1A) and 5-HT(2A/C) receptors activation
- Author
-
Anna M. Waszkielewicz, Barbara Filipek, Anna Rapacz, Henryk Marona, Agnieszka Kij, Jacek Sapa, Adam Galuszka, Grzegorz Kazek, Adrian Olczyk, Agata Siwek, Karolina Pytka, and Maria Walczak
- Subjects
Male ,medicine.medical_specialty ,5-HT2A receptor ,medicine.drug_class ,Xanthones ,Ritanserin ,Pharmacology ,Motor Activity ,Serotonergic ,Piperazines ,Mice ,Internal medicine ,medicine ,Receptor, Serotonin, 5-HT2C ,Animals ,Receptor, Serotonin, 5-HT2A ,5-HT receptor ,Swimming ,Behavior, Animal ,Dose-Response Relationship, Drug ,Chemistry ,Depression ,Brain ,Serotonin 5-HT1 Receptor Agonists ,Receptor antagonist ,Tail suspension test ,Antidepressive Agents ,Disease Models, Animal ,Endocrinology ,Mechanism of action ,Xanthenes ,Rotarod Performance Test ,Receptor, Serotonin, 5-HT1A ,medicine.symptom ,Serotonin 5-HT2 Receptor Agonists ,Behavioural despair test ,medicine.drug - Abstract
Xanthone derivatives have been shown to posses many biological properties. Some of them act within the central nervous system and show neuroprotective or antidepressant like properties. Taking this into account we investigated antidepressant like activity in mice and the possible mechanism of action of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one (HBK-11) - a new xanthone derivative. We demonstrated that HBK-11 produced antidepressant like effects in the forced swim test and tail suspension test, comparable to that of venlafaxine. The combined treatment with sub effective doses of HBK-11 and fluoxetine (but not reboxetine or bupropion) significantly reduced the immobility in the forced swim test. Moreover, the antidepressant like activity of HBK-11 in the aforementioned test was blocked by p-chlorophertylalanine, and significantly reduced by serotonergic $5-HT_{1A}$ receptor antagunist - WAY-1006335 and $5-HT_{2A/C}$ receptor antagonist - ritanserin. As none of the above treatments influenced the spontaneous locomotor activity, if can be concluded that HBK-11 mediates its activity through a serotonergic system, and its antidepressant like effect involves $5-HT_{1A}$ and $5-HT_{2A/C}$ receptor activation. Furthermore, at antidepressant like doses HBK-11 did not cause the mice to display locomotor deficits in rotarod or chimney rests. Considering the pharmacokinetic profile, HBK-11 demonstrated rapid absorption after i.p. administration, high clearance value, short terminal half-life, very high volume of distribution and incomplete bioavailabilily. The compound studied had good penetration into the brain tissue of mice. Since studied xanthone derivative seems to present interesting, untypical mechanism of antidepressant-like action i.e. $5-HT_{2A/C}$ receptor activation, it may have a potential in the treatment of depressive disorders, and surely requires further studies.
- Published
- 2015
17. Antidepressant- and anxiolytic-like effects of new dual 5-HT_{1A} and 5-HT_{7} antagonists in animal models
- Author
-
Barbara Mordyl, Adrian Olczyk, Karolina Pytka, Agata Siwek, Magdalena Jastrzębska-Więsek, Anna M. Waszkielewicz, Jacek Sapa, Adam Galuszka, Anna Partyka, Barbara Filipek, Marian J. Blachuta, Henryk Marona, Anna Wesołowska, Anna Rapacz, Grzegorz Kazek, and Monika Głuch-Lutwin
- Subjects
Male ,medicine.medical_specialty ,Elevated plus maze ,Phenylpiperazine ,Pharmacology ,Anxiety ,Serotonergic ,Imipramine ,chemistry.chemical_compound ,Mice ,Dopamine receptor D2 ,Internal medicine ,medicine ,Animals ,Rats, Wistar ,5-HT receptor ,Multidisciplinary ,Depression ,Rats ,Endocrinology ,chemistry ,Receptors, Serotonin ,Models, Animal ,Receptor, Serotonin, 5-HT1A ,Serotonin Antagonists ,Diazepam ,Locomotion ,Behavioural despair test ,medicine.drug ,Research Article - Abstract
The aim of this study was to further characterize pharmacological properties of two phenylpiperazine derivatives: 1-{2-[2-(2,6-dimethlphenoxy)ethoxy]ethyl}-4-(2-methoxyphenyl)piperazynine hydrochloride (HBK-14) and 2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl-4-(2- methoxyphenyl)piperazynine dihydrochloride (HBK-15) in radioligand binding and functional in vitro assays as well as in vivo models. Antidepressant-like properties were investigated in the forced swim test (FST) in mice and rats. Anxiolytic-like activity was evaluated in the four-plate test in mice and elevated plus maze test (EPM) in rats. Imipramine and escitalopram were used as reference drugs in the FST, and diazepam was used as a standard anxiolytic drug in animal models of anxiety. Our results indicate that HBK-14 and HBK-15 possess high or moderate affinity for serotonergic 5-HT2, adrenergic α1, and dopaminergic D2 receptors as well as being full 5-HT1A and 5-HT7 receptor antagonists. We also present their potent antidepressant-like activity (HBK-14—FST mice: 2.5 and 5 mg/kg; FST rats: 5 mg/kg) and (HBK-15—FST mice: 1.25, 2.5 and 5 mg/kg; FST rats: 1.25 and 2.5 mg/kg). We show that HBK-14 (four-plate test: 2.5 and 5 mg/kg; EPM: 2.5 mg/kg) and HBK-15 (four-plate test: 2.5 and 5 mg/kg; EPM: 5 mg/kg) possess anxiolytic-like properties. Among the two, HBK-15 has stronger antidepressant-like properties, and HBK-14 displays greater anxiolytic-like activity. Lastly, we demonstrate the involvement of serotonergic system, particularly 5-HT1A receptor, in the antidepressant- and anxiolytic-like actions of investigated compounds.
- Published
- 2015
18. Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice : the involvement of serotonergic system
- Author
-
Anna M. Waszkielewicz, Anna Rapacz, Adrian Olczyk, Barbara Filipek, Karolina Pytka, Małgorzata Zygmunt, and Jacek Sapa
- Subjects
Male ,Serotonin ,Stereochemistry ,Morpholines ,Xanthones ,Motor Activity ,Pharmacology ,Serotonergic ,Piperazines ,Antidepressant like ,Mice ,Reboxetine ,chemistry.chemical_compound ,Serotonin Agents ,Fluoxetine ,Xanthone ,medicine ,Animals ,Bupropion ,Postural Balance ,Swimming ,Depressive Disorder ,Fenclonine ,Neurotoxicity ,General Medicine ,medicine.disease ,Antidepressive Agents ,Piperazine ,Mechanism of action ,chemistry ,medicine.symptom ,Derivative (chemistry) ,Behavioural despair test - Abstract
The studied compound: 3-chloro-5-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}-9H-xanthen-9-one dihydrochloride (HBK-6) is a new xanthone derivative. In this study we investigated its antidepressant-like properties and possible mechanism of action.Antidepressant-like activity was evaluated in the forced swim test (FST) in mice. The influence on locomotor activity in mice was analyzed to determine whether the observed in FST effect is specific. Rotarod test was used to determine neurotoxic properties.HBK-6 reduced immobility time in mice in FST at the doses 5 and 10mg/kg, whereas fluoxetine (FX) at 15 mg/kg, reboxetine (RX) at 10mg/kg and bupropion (BPR) at 5mg/kg. Joint administration of sub-effective doses of HBK-6 and FX, but not RX or BPR, reduced immobility in mice in FST. HBK-6 at the dose 5mg/kg did not show activity in FST after pretreatment with p-chlorophenylalanine. The studied xanthone derivative at the doses 5 and 10mg/kg did not impair motor coordination in mice.We demonstrated that HBK-6 has a potent antidepressant-like activity in FST, stronger than that of FX and RX, and seems to mediate its effect through serotonergic system. Moreover, at antidepressant-like doses it does not show neurotoxic properties. Given the promising results, HBK-6 may have potential in the treatment of depression, but this needs extended studies.
- Published
- 2015
19. Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives
- Author
-
Anna M. Waszkielewicz, Elżbieta Wełna, Barbara Filipek, Grzegorz Satała, Karolina Pytka, Monika Jarzyna, Henryk Marona, Jacek Sapa, Paweł Żmudzki, Andrzej J. Bojarski, and Anna Rapacz
- Subjects
Stereochemistry ,Drug Evaluation, Preclinical ,Motor Activity ,Biochemistry ,Imipramine ,Piperazines ,chemistry.chemical_compound ,Mice ,Structure-Activity Relationship ,In vivo ,Drug Discovery ,medicine ,Animals ,Humans ,Receptor ,ED50 ,5-HT receptor ,Pharmacology ,Behavior, Animal ,Organic Chemistry ,Neurotoxicity ,medicine.disease ,Tail suspension test ,Antidepressive Agents ,Piperazine ,HEK293 Cells ,chemistry ,Receptors, Serotonin ,Rotarod Performance Test ,Receptor, Serotonin, 5-HT1A ,Molecular Medicine ,medicine.drug - Abstract
A series of new derivatives of N-(2-methoxyphenyl)piperazine have been synthesized for their affinity toward serotonergic receptors and for their potential antidepressant-like activity. They have been evaluated toward receptors 5-HT1A , 5-HT6 , and 5-HT7 , as well as in vivo in the tail suspension, locomotor activity, and motor co-ordination tests. All the tested compounds proved very good affinities toward 5-HT1A and 5-HT7 receptors. The most promising compound was 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride, exhibiting affinity toward receptors Ki
- Published
- 2015
20. Cardiovascular activity of the chiral xanthone derivatives
- Author
-
Anna Rapacz, Henryk Marona, Natalia Szkaradek, Dorota Żelaszczyk, Karolina Pytka, Barbara Filipek, Przemysław W. Szafrański, and Karolina Słoczyńska
- Subjects
Male ,Hydrochloride ,Xanthones ,Clinical Biochemistry ,Pharmaceutical Science ,Blood Pressure ,Propranolol ,Pharmacology ,Urapidil ,Biochemistry ,Mice ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,Xanthone ,medicine ,Animals ,Rats, Wistar ,Molecular Biology ,Carvedilol ,Antihypertensive Agents ,ED50 ,Dose-Response Relationship, Drug ,Molecular Structure ,Organic Chemistry ,Arrhythmias, Cardiac ,Rats ,Disease Models, Animal ,Blood pressure ,chemistry ,Toxicity ,Molecular Medicine ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
A series of 6 derivatives of xanthone were synthesized and evaluated for cardiovascular activity. The following pharmacological experiments were conducted: the binding affinity for adrenoceptors, the influence on the normal electrocardiogram, the effect on the arterial blood pressure, the effect on blood pressor response and prophylactic antiarrhythmic activity in adrenaline induced model of arrhythmia (rats, iv). Two compounds revealed nanomolar affinity for α1-adrenoceptor which was correlated with the strongest cardiovascular (antiarrhythmic and hypotensive) activity in animals' models. They were enantiomers of previously described (R,S)-4-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-9H-xanthen-9-one hydrochloride and revealed similar antiarrhythmic potential in adrenaline induced model of arrhythmia in rats after intravenous injection (ED50=0.53 mg/kg and 0.81 mg/kg, respectively). These values were lower than values obtained for reference drug urapidil. These compounds were more active in this experiment than urapidil (ED50=1.26 mg/kg). The compound 5 administered iv at doses of 0.62-2.5 mg/kg at the peak of arrhythmia prevented and/or reduced the number of premature ventricular beats in a statistically significant manner. The ED50 value was 1.20 mg/kg. The S-enantiomer (6) given at the same doses did not show therapeutic antiarrhythmic activity in this model. These compounds significantly decreased the systolic and diastolic blood pressure throughout the whole observation period in anesthetized, normotensive rats. The studied enantiomers showed higher toxicity than urapidil, but imperceptibly higher that another cardiovascular drugs, that is, carvedilol or propranolol. They were also evaluated for mutagenic potential in the Ames (Salmonella) test. It was found that at the concentrations tested the compounds were non mutagenic when compared to solvent control. Results were quite promising and suggested that in the group of xanthone derivatives new potential antiarrhythmics and hypotensives might be found.
- Published
- 2015
21. The antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice
- Author
-
Anna M. Waszkielewicz, Adrian Olczyk, Karolina Pytka, Adam Galuszka, Klaudia Lustyk, Jacek Sapa, Elzbieta Zmudzka, Henryk Marona, Anna Rapacz, and Filipek Barbara
- Subjects
0301 basic medicine ,Hydrochloride ,Xanthones ,Pharmacology ,Piperazines ,moclobemide ,Buspirone ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,anxiolytic-like ,Xanthone ,Moclobemide ,Avoidance Learning ,medicine ,Animals ,behavioral tests ,Pharmacology (medical) ,buspirone ,xanthone derivative ,Behavior, Animal ,Antidepressant-like ,Antidepressive Agents ,Tail suspension test ,Piperazine ,030104 developmental biology ,Anti-Anxiety Agents ,chemistry ,Antidepressant ,030217 neurology & neurosurgery ,Research Article ,medicine.drug ,Behavioural despair test - Abstract
Objectives: Xanthones are flavonoids with numerous activities, including antioxidant, antidepressant., or anxiolytic-like. Therefore, the aim of our study was to determine antidepressant- and anxiolytic-like properties of four xanthone derivatives (3-chloro-5-[(4-methylpiperazin-1-yl)methyl]-9H-xanthen-9-one dihydrochloride [HBK-5], 6-methoxy-2-[(4-methylpiperazin-1-yl) methyl]-9H-xanthen-9-one dihydrochloride, 2-[(4-benzylpiperazin-1-yl) methyl]-6-methoxy-9H-xanthen-9-one dihydrochloride, 2-{[4-(2-methoxyphenyl) piperazin-1-yl] methyl}-9H-xanthen-9-one hydrochloride), as well as the influence on cognitive and motor function of active compounds, using animal models. Materials and Methods: To determine the antidepressant-like activity, we used forced swim test (FST) and tail suspension test (TST) in mice. We evaluated anxiolytic-like properties in the four-plate test in mice. We studied the influence on cognitive and motor function in passive avoidance step-through and chimney tests, respectively. Results: The antidepressant-like activity (in both FST and TST) showed only HBK-5. Moreover, the compound was also active in the four-plate test, which suggests that it possessed anxiolytic-like properties. HBK-5 did not cause any cognitive and motor deficits in mice at antidepressant- and anxiolytic-like doses. Conclusions: HBK-5 may have potential in the treatment of depression or anxiety disorders, but this issue needs further studies.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.